and 36 CFR part 242 require that persons engaged in taking fish, shellfish, and wildlife on public lands in Alaska for subsistence uses must apply for and obtain a permit to do so and comply with reporting provisions of that permit. We use the following forms to collect information from qualified rural residents for subsistence harvest:

(1) FWS Form 3–2326 (Federal Subsistence Hunt Application, Permit,

and Report).

(2) FWS Form 3–2327 (Designated Hunter Permit Application, Permit, and Report).

(3) FWS Form 3–2328 (Federal Subsistence Fishing Application, Permit, and Report).

(4) FWS Form 3–2378 (Designated Fishing Permit Application, Permit, and Report).

(5) FWS Form 3–2379 (Federal Subsistence Customary Trade Recordkeeping Form).

We use the information collected to evaluate:

- Eligibility of applicant.
- Subsistence harvest success.
- Effectiveness of season lengths, harvest quotas, and harvest restrictions.
 - Hunting patterns and practices.
 - · Hunter use.

The Federal Subsistence Board uses the harvest data, along with other information, to set future season dates and harvest limits for Federal subsistence resource users. These seasons and harvest limits are set to meet the needs of subsistence users without adversely impacting the health of existing animal populations.

Also included in this ICR are three forms associated with recruitment and selection of members for regional advisory councils.

- (1) FWS Form 3–2321 (Federal Subsistence Regional Advisory Council Membership Application/Nomination).
- (2) FWS Form 3–2322 (Regional Advisory Council Candidate Interview).
- (3) FWS Form 3–2323 (Regional Advisory Council Reference/Key Contact Interview).

The member selection process begins with the information that we collect on the application. Ten interagency review panels interview all applicants and nominees, their references, and regional key contacts. These contacts are all based on the information that the applicant provides on the application form. The information that we collect through the application form and subsequent interviews is the basis of the Federal Subsistence Board's recommendations to the Secretaries of the Interior and Agriculture for appointment and reappointment of council members.

In addition to the above forms, regulations at 50 CFR part 100 and 36 CFR part 242 contain requirements for the collection of information. We collect nonform information on:

- (1) Repeal of Federal subsistence rules and regulations (50 CFR 100.14 and 36 CFR 242.14).
- (2) Proposed changes to Federal subsistence regulations (50 CFR 100.18 and 36 CFR 242.18).
- (3) Special action requests (50 CFR 100.19 and 36 CFR 242.19).
- (4) Requests for reconsideration (50 CFR 100.20 and 36 CFR 242.20).
- (5) Requests for permits and reports, such as traditional religious/cultural/educational permits, fishwheel permits, fyke net permits, and under-ice permits (50 CFR 100.25–27 and 36 CFR 242.25–27).

Comments Received and Our Responses

Comments: On October 15, 2015, we published in the Federal Register (80 FR 62091) a notice of our intent to request that OMB renew approval for this information collection. In that notice, we solicited comments for 60 days, ending on December 14, 2015. We did not receive any comments in response to that notice.

Request for Public Comments

We again invite comments concerning this information collection on:

- Whether or not the collection of information is necessary, including whether or not the information will have practical utility;
- The accuracy of our estimate of the burden for this collection of information:
- Ways to enhance the quality, utility, and clarity of the information to be collected; and
- Ways to minimize the burden of the collection of information on respondents.

Comments that you submit in response to this notice are a matter of public record. Before including your address, phone number, email address, or other personal identifying information in your comment, you should be aware that your entire comment, including your personal identifying information, may be made publicly available at any time. While you can ask OMB and us in your comment to withhold your personal identifying information from public review, we cannot guarantee that it will be done.

Dated: February 19, 2016.

Tina A. Campbell,

Chief, Division of Policy, Performance, and Management Programs, U.S. Fish and Wildlife Service.

[FR Doc. 2016–03819 Filed 2–23–16; 8:45 am] **BILLING CODE 4333–15–P**

JUDICIAL CONFERENCE OF THE UNITED STATES

Meeting of the Judicial Conference Advisory; Committee on Rules of Appellate Procedure

AGENCY: Advisory Committee on Rules of Appellate Procedure, Judicial Conference of the United States.

ACTION: Notice of open meeting.

SUMMARY: The Advisory Committee on Rules of Appellate Procedure will hold a meeting on April 5, 2016, which will continue the morning of April 6, 2016, if necessary. The meeting will be open to public observation but not participation. An agenda and supporting materials will be posted at least 7 days in advance of the meeting at: http://www.uscourts.gov/rules-policies/records-and-archives-rules-committees/agenda-books.

DATES: April 5–6, 2016. *Time:* 9:00 a.m. to 5:00 p.m.

ADDRESSES: Colorado Supreme Court, 2 East 14th Avenue, Conference Room C4244, Denver, CO 80203.

FOR FURTHER INFORMATION CONTACT:

Rebecca A. Womeldorf, Rules Committee Secretary, Rules Committee Support Office, Administrative Office of the United States Courts, Washington, DC 20544, telephone (202) 502–1820.

Dated: February 17, 2016.

Rebecca A. Womeldorf,

Rules Committee Secretary. [FR Doc. 2016–03865 Filed 2–23–16; 8:45 am] BILLING CODE 2210–55–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Cayman Chemical Company

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in

Schedule

Controlled substance

Schedule

Controlled substance

accordance with 21 CFR 1301.33(a) on or before April 25, 2016.

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator") pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR 1301.33(a), this is notice that on August 24, 2015, Cayman Chemical Company, 1180 East Ellsworth Road, Ann Arbor, Michigan 48108 applied to be registered as a bulk manufacturer of the following basic classes of controlled substances:

| Controlled substance | Schedule |
|---|----------|
| 3-Fluoro-N-methylcathinone (3–FMC) (1233). | 1 |
| Cathinone (1235) | 1 |
| Methcathinone (1237) | 1 |
| 4-Fluoro-N-methylcathinone (4–FMC) (1238). | 1 |
| Pentedrone (α- methylaminovalerophenone) (1246). | I |
| Mephedrone (4-Methyl-N-methylcathinone) (1248). | I |
| 4-Methyl-N-ethylcathinone (4–MEC) (1249). | I |
| Naphyrone (1258) | 1 |
| N-Ethylamphetamine (1475) | 1 |
| N,N-Dimethylamphetamine (1480) | 1 |
| Aminorex (1585) | 1 |
| 4-Methylaminorex (cis isomer) (1590). | 1 |
| Gamma Hydroxybutyric Acid (2010). | I |
| Methaqualone (2565) | 1 |
| Mecloqualone (2572) | 1 |
| JWH–250 (1-Pentyl-3-(2-methoxyphenylacetyl)indole) (6250). | I |
| SR-18 (Also known as RCS-8) (1-Cyclohexylethyl-3-(2-methoxyphenylacetyl)indole) (7008). | 1 |

| 5-Flouro-UR-144 and XLR11 [1- | 1 | 2-(4-Ethylthio-2,5- | 1 |
|--|------|---|---|
| (5-Fluoro-pentyl)1H-indol-3- yl](2,2,3,3- | | dimethoxyphenyl) ethanamine (2C-T-2) (7385). | |
| tetramethylcyclopropy- | | 3,4,5-Trimethoxyamphetamine | 1 |
| I)methanone (7011). | | (7390). | |
| AB–FUBINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4- | I | 4-Bromo-2,5- dimethoxyamphetamine (7391). | I |
| fluorobenzyl)-1H-indazole-3- | | 4-Bromo-2,5- | 1 |
| carboxamide) (7012). | | dimethoxyphenethylamine | |
| JWH-019 (1-Hexyl-3-(1-naph-thoyl)indole) (7019). | I | (7392). 4-Methyl-2,5- | ı |
| AB-PINACA (N-(1-amino-3-meth- | 1 | dimethoxyamphetamine (7395). | 1 |
| yl-1-oxobutan-2-yl)-1-pentyl-1H- | | 2,5-Dimethoxyamphetamine | 1 |
| indazole-3-carboxamide) (7023). THJ-2201 [1-(5-fluoropentyl)-1H- | 1 | (7396). JWH–398 (1-Pentyl-3-(4-chloro-1- | 1 |
| indazol-3-yl](naphthalen-1- | | naphthoyl)indole) (7398). | ' |
| yl)methanone (7024). AB-CHMINACA (N-(1-amino-3- | ı | 2,5-Dimethoxy-4- | 1 |
| AB-CHMINACA (N-(1-amino-3-methyl-1-oxobutan-2-yl)-1- | Ī | ethylamphetamine (7399). 3,4-Methylenedioxyamphetamine | ı |
| (cyclohexylmethyl)-1H-indazole- | | (7400). | |
| 3-carboxamide (7031). ADB-PINACA (N-(1-amino-3,3-di- | 1 | 5-Methoxy-3,4- | 1 |
| methyl-1-oxobutan-2-yl)-1- | ' | methylenedioxyamphetamine (7401). | |
| pentyl-1H-indazole-3- | | N-Hydroxy-3,4- | 1 |
| carboxamide) (7035). APINACA and AKB48 N-(1- | 1 | methylenedioxyamphetamine | |
| Adamantyl)-1-pentyl-1H-inda- | | (7402). 3,4-Methylenedioxy-N- | ı |
| zole-3-carboxamide (7048). | | ethylamphetamine (7404). | ' |
| JWH-081 (1-Pentyl-3-(1-(4-methoxynaphthoyl)indole) | I | 3,4- | 1 |
| (7081). | | Methylenedioxymethamphetam- ine (7405). | |
| SR-19 (Also known as RCS-4) | I | 4-Methoxyamphetamine (7411) | 1 |
| (1-Pentyl-3-[(4-methoxy)-ben-zoyl]indole (7104). | | 5-Methoxy-N-N- | 1 |
| JWH-018 (also known as AM678) | 1 | dimethyltryptamine (7431). Alpha-methyltryptamine (7432) | ı |
| (1-Pentyl-3-(1-naphthoyl)indole) | | Diethyltryptamine (7434) | i |
| (7118). JWH–122 (1-Pentyl-3-(4-methyl-1- | 1 | Dimethyltryptamine (7435) | ! |
| naphthoyl)indole) (7122). | | Psilocybin (7437) Psilocyn (7438) | |
| UR-144 (1-Pentyl-1H-indol-3- yl)(2,2,3,3- | Ī | 5-Methoxy-N,N- | i |
| tetramethylcyclopropy- | | diisopropyltryptamine (7439). | |
| I)methanone (7144). | | N-Benzylpiperazine (7493) 2-(2,5-Dimethoxy-4- | |
| JWH-073 (1-Butyl-3-(1-naph-thoyl)indole) (7173). | Ī | methylphenyl)ethanamine (2C- | ' |
| JWH–200 (1-[2-(4- | 1 | D) (7508). | |
| Morpholinyl)ethyl]-3-(1-naph- | | 2-(2,5-Dimethoxy-4- ethylphenyl)ethanamine (2C–E) | I |
| thoyl)indole) (7200). AM–2201 (1-(5-Fluoropentyl)-3-(1- | 1 | (7509). | |
| naphthoyl)indole) (7201). | • | 2-(2,5- | 1 |
| JWH–203 (1-Pentyl-3-(2-chlorophenylacetyl)indole) | 1 | Dimethoxyphenyl)ethanamine (2C-H) (7517). | |
| (7203). | | 2-(4-lodo-2,5- | 1 |
| PB-22 (Quinolin-8-yl 1-pentyl-1H- | 1 | dimethoxyphenyl)ethanamine | |
| indole-3-carboxylate) (7222). 5F-PB-22 (Quinolin-8-yl 1-(5- | 1 | (2C–I) (7518). 2-(4-Chloro-2,5- | ı |
| fluoropentyl)-1H-indole-3- | • | dimethoxyphenyl)ethanamine | |
| carboxylate) (7225). | | (2C–C) (7519). | |
| Alpha-ethyltryptamine (7249) CP–47,497 (5-(1,1- | | 2-(2,5-Dimethoxy-4-nitro- phenyl)ethanamine (2C–N) | I |
| Dimethylheptyl)-2-[(1R,3S)-3- | | (7521). | |
| hydroxycyclohexyl-phenol) | | 2-(2,5-Dimethoxy-4-(n)- | I |
| (7297). CP-47,497 C8 Homologue (5- | ı | propylphenyl)ethanamine (2C–P) (7524). | |
| (1,1-Dimethyloctyl)-2-[(1R,3S)3- | | 2-(4-Isopropylthio)-2,5- | 1 |
| hydroxycyclohexyl-phenol) | | dimethoxyphenyl)ethanamine | |
| (7298). Lysergic acid diethylamide (7315) | 1 | (2C–T–4) (7532). MDPV (3,4- | 1 |
| 2,5-Dimethoxy-4-(n)- | i | Methylenedioxypyrovalerone) | |
| propylthiophenethylamine) (2C- | | (7535). | 1 |
| T-7) (7348). Marihuana (7360) | 1 | 2-(4-bromo-2,5-dimethoxyphenyl)- N-(2-methoxy- | I |
| Tetrahydrocannabinols (7370) | 1 | benzyl)ethanamine (25B- | |
| Mescaline (7381) | | NBOMe) (7536). | l |
| | | | |

| Controlled substance | Schedule |
|--|----------|
| 2-(4-chloro-2,5-dimethoxyphenyl)- N-(2-methoxy- | I |
| benzyl)ethanamine (25C– NBOMe) (7537). | |
| 2-(4-iodo-2,5-dimethoxyphenyl)-N- (2-methoxybenzyl)ethanamine | 1 |
| (25I-NBOMe) (7538). | |
| Methylone (3,4-Methylenedioxy-N-methylcathinone) (7540). | |
| Butylone (7541) | |
| Pentylone (7542) | I |
| alpha-pyrrolidinopentiophenone (α-PVP) (7545). | |
| alpha-pyrrolidinobutiophenone (α-PBP) (7546). | |
| AM-694 (1-(5-Fluoropentyl)-3-(2-iodobenzoyl)indole) (7694). | |
| Acetyldihydrocodeine (9051) | ! |
| Benzylmorphine (9052) | ! |
| Codeine-N-oxide (9053) | 1 |
| Desomorphine (9055) | 1 |
| Dihydromorphine (9145) | 1 |
| Heroin (9200) | ! |
| Morphine-N-oxide (9307) | ! |
| Normorphine (9313) | ! |
| Tilidine (9750) | ! |
| Acetyl Fentanyl (N-(1- | I |
| phenethylpiperidin-4-yl)-N- | |
| phenylacetamide) (9821). | |
| Amphetamine (1100) | ll |
| Methamphetamine (1105) | ll |
| Lisdexamfetamine (1205) | III |
| Methylphenidate (1724) | II |
| Amobarbital (2125) | ll |
| Pentobarbital (2270) | II |
| Secobarbital (2315) | ll |
| Phencyclidine (7471) | III |
| Phenylacetone (8501) | II |
| Cocaine (9041) | II |
| Codeine (9050) | II |
| Dihydrocodeine (9120) | II |
| Oxycodone (9143) | II. |
| Hydromorphone (9150) | ll |
| Ecgonine (9180) | II |
| Ethylmorphine (9190) | II |
| Hydrocodone (9193) | II |
| Levomethorphan (9210) | III |
| Levorphanol (9220) | ll |
| Meperidine (9230) | II |
| Meperidine intermediate-B (9233) | II |
| Methadone (9250) | II |
| Dextropropoxyphene, bulk. | |
| (non-dosage forms) (9273) | II |
| Morphine (9300) | II |
| Thebaine (9333) | II |
| Oxymorphone (9652) | II |
| Sufentanil (9740) | II. |
| Tapentadol (9780) | II |
| Fentanyl (9801) | II |

The company plans to manufacture reference standards for distribution to their research and forensics customers.

In reference to drug codes 7360 (marihuana) and 7370 (tetrahydrocannabinols), the company plans to bulk manufacture these drugs as synthetic. No other activities for these drug codes are authorized for this registration.

Dated: February 16, 2016.

Louis J. Milione,

Deputy Assistant Administrator.

[FR Doc. 2016–03854 Filed 2–23–16; 8:45 am]

BILLING CODE 4410-09-P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration [Docket No. DEA-392]

Bulk Manufacturer of Controlled Substances Application: Janssen Pharmaceutical, Inc.

ACTION: Notice of application.

DATES: Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration in accordance with 21 CFR 1301.33(a) on or before April 25, 2016

ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/ODW, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated her authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Deputy Assistant Administrator of the DEA Office of Diversion Control ("Deputy Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, appendix to subpart R.

In accordance with 21 CFR
1301.33(a), this is notice that on
November 12, 2015, Janssen
Pharmaceutical, Inc., 1440 Olympic
Drive, Athens, Georgia 30601 applied to
be registered as a bulk manufacturer of
the following basic classes of controlled
substances:

| Controlled substance | Schedule |
|------------------------|------------------|
| Methylphenidate (1724) | |

| Controlled substance | Schedule |
|----------------------|----------|
| Tapentadol (9780) | II |
| Fentanyl (9801) | II |

The company plans to manufacture the above-listed controlled substances in bulk for distribution to its customers.

Dated: February 16, 2016.

Louis J. Milione,

Deputy Assistant Administrator. [FR Doc. 2016–03852 Filed 2–23–16; 8:45 am] BILLING CODE 4410–09–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]

Manufacturer of Controlled Substances Registration: Cedarburg Pharmaceuticals, Inc.

ACTION: Notice of registration.

SUMMARY: Cedarburg Pharmaceuticals, Inc. applied to be registered as a manufacturer of certain basic classes of controlled substances. The Drug Enforcement Administration (DEA) grants Cedarburg Pharmaceuticals, Inc. registration as a manufacturer of those controlled substances.

SUPPLEMENTARY INFORMATION: By notice dated September 16, 2015, and published in the Federal Register on September 23, 2015, 80 FR 57390, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024 applied to be registered as a manufacturer of certain basic classes of controlled substances. No comments or objections were submitted for this notice.

The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of Cedarburg Pharmaceuticals, Inc. to manufacture the basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company's maintenance of effective controls against diversion by inspecting and testing the company's physical security systems, verifying the company's compliance with state and local laws, and reviewing the company's background and history.

Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above-named company is granted registration as a bulk manufacturer of the following basic classes of controlled substances: